文献速递乳腺癌放疗放疗物理与技术

三维表面成像在乳腺癌放疗中的应用:临床研究新工具?

Three-dimensional surface imaging in breast cancer: a new tool for clinical studies?
PubMed 文献 · Radiat Oncol · 2020-02-28

本研究采用结构光三维表面成像(3DSI)对接受常规分割放疗(CF-RT)或大分割放疗(HF-RT)的乳腺癌患者进行每周成像,分析乳房体积和皮肤外观变化。结果显示CF-RT组乳房红斑发生率显著高于HF-RT组(93.3% vs 34.8%,p=0.003),且整个队列治疗侧乳房体积从基线(379±196 mL)至3个月随访(437±224 mL)显著增加,未治疗侧无显著变化。3DSI有望作为无创工具客观监测乳腺癌放疗的美容效果和早期反应。

要点

  • CF-RT组乳房红斑发生率显著高于HF-RT组(93.3% vs 34.8%,p=0.003)。
  • 治疗侧乳房体积从基线至3个月随访显著增加(379±196 mL至437±224 mL)。
  • 3DSI可无创、客观地记录乳腺癌放疗后的皮肤和体积变化。

核心结论

  • 3DSI是首项用于乳腺癌放疗患者无创客观记录的三维结构光技术,可区分不同放疗分割方式的结局。

研究设计与样本

  • 前瞻性概念验证研究,纳入接受CF-RT或HF-RT的乳腺癌患者,放疗期间及随访时每周行3DSI成像。
  • 使用便携式Artec Eva扫描仪记录三维表面图像,分析乳房体积和皮肤外观变化。
  • 共分析38例患者、214次乳房成像 sessions。

主要发现

  • CF-RT组乳房红斑发生率显著高于HF-RT组(93.3% vs 34.8%,p=0.003)。
  • 整个队列治疗侧乳房体积从基线(379±196 mL)至3个月随访(437±224 mL)显著增加(p<0.05)。
  • 治疗侧乳房体积从放疗第3周(391±198 mL)至3个月随访显著增加(p<0.05)。
  • CF-RT和HF-RT两个亚组中,基线至3个月随访治疗侧乳房体积均显著增加(p<0.05)。
  • 未治疗的健康乳房未见统计学显著的皮肤或体积变化。

临床怎么用

  • 3DSI可作为无创工具客观精确监测乳腺癌放疗中的乳房变化。
  • 临床可利用3DSI客观区分不同放疗分割方式的结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Three-dimensional Surface Imaging (3DSI) is a well-established method to objectively monitor morphological changes in the female breast in the field of plastic surgery. In contrast, in radiation oncology we are still missing effective tools, which can objectively and reproducibly assess and document adverse events in breast cancer radiotherapy within the framework of clinical studies. The aim of the present study was to apply structured-light technology as a non-invasive and objective approach for the documentation of cosmetic outcome and early effects of breast radiotherapy as a proof of principle. METHODS: Weekly 3DSI images of patients receiving either conventionally fractionated radiation treatment (CF-RT) or hypofractionated radiation treatment (HF-RT) were acquired during the radiotherapy treatment and clinical follow-up. The portable Artec Eva scanner (Artec 3D Inc., Luxembourg) recorded 3D surface images for the analysis of breast volumes and changes in skin appearance. Statistical analysis compared the impact of the two different fractionation regimens and the differences between the treated and the contralateral healthy breast. RESULTS: Overall, 38 patients and a total of 214 breast imaging sessions were analysed. Patients receiving CF-RT showed a significantly higher frequency of breast erythema compared to HF-RT (93.3% versus 34.8%, p = 0.003) during all observed imaging sessions. Moreover, we found a statistically significant (p < 0.05) volumetric increase of the treated breast of the entire cohort between baseline (379 ± 196 mL) and follow-up imaging at 3 months (437 ± 224 mL), as well as from week 3 of radiotherapy (391 ± 198 mL) to follow-up imaging. In both subgroups of patients undergoing either CF-RT or HF-RT, there was a statistically significant increase (p < 0.05) in breast volumes between baseline and 3 months follow-up. There were no statistically significant skin or volumetric changes of the untreated healthy breasts. CONCLUSIONS: This is the first study utilizing 3D structured-light technology as a non-invasive and objective approach for the documentation of patients receiving breast radiotherapy. 3DSI offers potential as a non-invasive tool to objectively and precisely monitor the female breast in a radiooncological setting, allowing clinicians to objectively distinguish outcomes of different therapy modalities.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Koban KC, Etzel L, Li Z, et al. Three-dimensional surface imaging in breast cancer: a new tool for clinical studies? Radiat Oncol. 2020. PMID: 32111228. doi:10.1186/s13014-020-01499-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。